Related Experiment Video
Updated: Jul 23, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Potential for biosimilars in rheumatology in Africa
Mohamed Hassan Abu-Zaid1, Adewale Adebajo2,3, Yasser El Miedany4,5
1Rheumatology and Rehabilitation, Tanta University Faculty of Medicine, Tanta, Egypt drmhassan113@yahoo.com.
Abstract:
Biosimilars are products which are highly similar to a reference biologic product (RBP). In Africa, regulatory frameworks for biosimilar approval are still in development in many countries and few biosimilars for rheumatic diseases are currently available. The use of biosimilar medicines in Africa provides an important opportunity to treat more rheumatology patients with biologic drugs. This editorial aims to shed a light on the potential benefits, challenges and current efforts, regarding the use of biosimilars in Africa in Rheumatology.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Mesenchymal Stem Cells
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The JAK-STAT Signaling Pathway

